| Bioactivity | Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research[1]. |
| Invitro | Degarelix shows only very weak histamine-releasing properties and the lowest capacity for histamine release among the antagonists of LHRH, including Cetrorelix (HY-P0009), Abarelix (HY-13534), and Ganirelix (HY-P1628)[1].Degarelix (1 nM-10 μM, 0-72 h) reduces cell viability in all prostate cell lines (WPE1-NA22, WPMY-1, BPH-1, VCaP cells), with the exception of the PC-3 cells[2].Degarelix (10 μM, 0-72 h) exerts a direct effect on prostate cell growth through apoptosis[2]. Cell Viability Assay[2] Cell Line: |
| Name | Degarelix acetate hydrate |
| CAS | 934246-14-7 |
| Formula | C82H103ClN18O16.xC2H4O2.xH2O |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Degarelix acetate hydrate
CAS: 934246-14-7 F: C82H103ClN18O16.xC2H4O2.xH2O W:
Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagoni
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.